Beneficial effects of a nobiletin-rich formulated supplement of Sikwasa (C. depressa) peel on cognitive function in elderly Japanese subjects; A multicenter, randomized, double-blind, placebo-controlled study

Shizuo Yamada1 | Michiyo Shirai1 | Ken Ono2 | Toshiaki Teruya3 | Aki Yamano4 | Je Tae Woo4,5

1Center for Pharma-Food Research, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan
2Izu Health & Medical Center, Shizuoka, Japan
3Faculty of Education, University of the Ryukyus, Okinawa, Japan
4Okinawa Research Center Co., Ltd, Uruma, Japan
5Department of Biological Chemistry, College of Bioscience and Biotechnology, Chubu University, Kasugai, Japan

Correspondence
Shizuo Yamada, Center for Pharma-Food Research (CPFR), Graduate School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.
Email: yamada@u-shizuoka-ken.ac.jp

Funding information
The present study was partly supported by a fund from Okinawa Research Co., Ltd

Abstract
Background: Nobiletin exerts beneficial effects on cognitive function in various animal models of Alzheimer's disease. The present study aimed to investigate the benefits and safety of a combination food of nobiletin-rich extract from C. depressa peel for healthy elderly subjects.

Methods: The nobiletin-containing test food (Nobilex®) comprised high-purity nobiletin powder combined with dried root powder of K. parviflora and dried lead powder of P. japonicum and was administered to elderly Japanese subjects once a day for 16 weeks. The Japanese version of the Wechsler Memory Scaled-Revised (WMS-R) was used as a primary evaluation item for the assessment of global memory. Data from a protocol-matched population (Per Protocol Set: PPS) (n = 108) were analyzed.

Results: The scores of "general memory" or "visual memory" in the indices of WMS-R were significantly higher in the nobiletin-containing test food group than in the placebo group. The difference in the total WMS-R score was significantly higher in the test-food group (9.0 ± 7.20) than in the placebo group (5.9 ± 7.70). An age-stratified analysis of the WMS-R test showed similar changes in subjects aged ≤74 years to those in the overall subject population. In the stratified analysis involving subjects with an MMSE-J score of between 24 and 28, the "figural memory" subscale score in WMS-R was significantly higher in the test food group than in the placebo group.

Conclusion: The present results indicate that the nobiletin-containing test food is beneficial for improving memory dysfunction in healthy elderly subjects.

Keywords
elderly subject, memory function, Nobiletin, WMS-R
1 | INTRODUCTION

The number of patients with dementia worldwide was 46.8 million in 2015 and is estimated to increase to 131.5 million by 2050 (Prince et al., 2015). In Japan, the incidence of cognitive/memory disorders, represented by dementia, has increased with the expanding elderly population. Alzheimer’s disease (AD), an age-related neurodegenerative disorder, is the most common type of dementia. The pathological hallmarks of AD are accumulation of amyloid-β (Aβ) plaques, neurofibrillary tangles, and neuronal loss (Jack et al., 2013). It is characterized by impaired cholinergic function in the brain, and donepezil has been used in the treatment of AD as a cholinergic enhancer to inhibit acetylcholinesterase (AChE), resulting in increased acetylcholine levels in synaptic clefts. However, since current medical treatments do not significantly attenuate the progression of this disease, more efficient therapeutic and preventive interventions are imperative for sustaining a healthy elderly population.

The development of brain function-improving foods that may be safely consumed for prevention needs to be accelerated. Citrus fruits contain flavonoids that exhibit various physiological activities (Nogata et al., 2006). They have been utilized as fruits, foods, and supplements that may exert favorable effects on health. Among these flavonoids, the various physiological functions of polymethoxylated flavonoids (PMFs) have recently been investigated. Nobiletin, 3’,4’,5,6,7,8-hexamethoxyflavone, is a representative PMF compound, that is abundant in the peels of citrus fruits, such as Sikwasa (Citrus depressa) (Nogata et al., 2006). We developed a method to manufacture material with high-purity nobiletin and tangeretin from citrus peel, C. depressa, whose process includes dehydrating the peel, extracting the dried peel with ethanol, and treating extracts with alkaline (Woo, 2017). This material contains 65% nobiletin and 25% tangeretin, as the main components, with sinensetin as a minor component. Nobiletin has been reported to exert multiple biological effects, such as anti-inflammatory, anti-tumor, and neuroprotective activities (Choi et al., 2011; Lee et al., 2010; Miyamoto et al., 2008; Mulvihill et al., 2011; Roza et al., 2007; Tanaka et al., 2004; Yasunaga et al., 2016). The beneficial effects of nobiletin against neurodegenerative disorders, including AD, have recently been extensively reviewed (Braidy et al., 2017; Nakajima & Ohizumi, 2019). Furthermore, its beneficial effects on cognitive function in various animal models of AD have been characterized (Nakajima & Ohizumi, 2019; Onozuka et al., 2008). A human study on combination therapy with a dried nobiletin-rich C. reticulata peel extract containing nobiletin and donepezil demonstrated significant improvements in the combination group relative to the donepezil-treated group (Seki et al., 2013). A cohort study on elderly Japanese subjects by Zhang et al. (2017) revealed that the frequent consumption of citrus was associated with a reduced risk of the onset of dementia, even after adjustments for possible confounding factors.

An Okinawan material component, Kaempferia parviflora extract containing PMFs, was shown to reduce the cellular growth insufficiency at nerve regeneration sites in the hippocampus and thereby attenuate cognitive dysfunction (Plaingam et al., 2017). Furthermore, Peucedam japonicum extract, which has traditionally been used in Okinawa based on the assumption that the consumption of a stump each day may prolong the life by one day, exhibited antiobesity (Nugara et al., 2014) and anti-inflammatory activities (Chun et al., 2018). Therefore, the present study aimed to investigate the benefits and safety of a combination food of nobiletin-rich extract from C. depressa peel with extracts of K. parviflora and P. japonicum, in healthy elderly subjects with MMSE scores of between 24 and 30, and memory lapses. A randomized, double-blind, placebo-controlled study was conducted to establish whether this product promotes cognitive improvements in humans.

2 | METHODS AND MATERIALS

2.1 | Test food

Sikwasa (C. depressa) is a citrus fruit that grows naturally in the Northern area of Okinawa, with an annual harvest of approximately 4,000 t. A large portion is processed into juice, leaving behind tons of citrus peels as industrial waste. The Okinawa Research Center Organization established a method to manufacture high-purity nobiletin powder (PMF90: nobiletin, 65%; tangeretin, 25%) from the residual by-product, through isolation using ethanol extraction/concentration and an alkaline treatment (Woo, 2017). The test food enriched with high-purity nobiletin powder, combined with extracts of K. parviflora and P. japonicum, is commercially available as a supplement (Nobilex®) to improve the quality of life (QOL) of the elderly. One capsule contains the dried powder extract (containing 10.0 mg nobiletin and 5.8 mg tangeretin) of C. depressa peel, the dried root powder (126.7 mg) of K. parviflora and the dried leaf powder of P. japonicum (33.3 mg). These plant extracts were not included in the placebo capsules. Three capsules of the nobiletin-containing test food or placebo food were administered to each subject once a day for 16 weeks.

2.2 | Study design

The study was conducted as a randomized, double-blind, placebo-controlled trial. Its protocol was approved as a specific clinical study by the Clinical Research Examination Ethical Committee of Hamamatsu Medical University on October 4, 2019, and registered to the Japan Registry of Clinical Trials (JRCT) (JRCTs041190073) on October 7, 2019. The present study was conducted in accordance with the Helsinki Declaration and “Clinical Research methods and regulations for Clinical Research methods”, considering subjects’ human rights and safety/welfare. Study participants were recruited by medical institutions and community organizations. The study contents were sufficiently explained to individuals wishing to participate in this study, and written informed consent was obtained. The study period was between October 7, 2019, and March 31, 2020. There were no changes in the protocol.
2.3 | Subjects

The number of subjects was 122, consisting of healthy subjects who consulted the Seishukai Takido Medical Clinic, Shujikai Hagiwara Medical Clinic, or Izu Health & Medical Center as well as elderly residents of the area who were able to participate/cooperate. Primary selection criteria included healthy males and females, aged ≥65 years, with memory lapses and an MMSE-J score of ≥24. After obtaining written informed consent on recruitment, subjects who met the selection criteria, but not the exclusion criteria, were selected.

2.4 | Selection criteria

- Written informed consent was obtained from the individual before participating in this study.
- Individuals aged ≥65 years, with memory lapses.
- Individuals who were able to consume the test food during the study period.
- Individuals who were able to write a diary during the consumption period.
- Individuals with an MMSE-J (Folstein et al., 1975) score of ≥24.

2.5 | Exclusion criteria

- Patients with dementia.
- Individuals with a history of stroke, subarachnoid hemorrhage, cerebral infarction, cerebral hemorrhage, or brain contusion/head trauma requiring treatment/admission/surgery.
- Individuals with a history of epilepsy or diabetes or those being treated at outpatient clinics due to these diseases.
- Individuals with potential allergies to components of the test food.
- Individuals receiving drugs that may influence cognitive function (antipsychotic drugs, anxiolytics, antidepressants, anti-Parkinson drugs, antimanic drugs, antiepileptic drugs, and drugs for dementia).
- Individuals participating or planning to participate in other clinical studies at the start of this study.
- Individuals considered to be ineligible by the chief investigator.

2.6 | Randomization and blinding

The subjects of this study comprised 122 healthy elderly persons enrolled, and they were randomly assigned to a placebo or nobiletin-containing test food group using the permuted block method. The assignment table was sealed, stored until the completion of this study, and opened after its completion. We confirmed that there were no significant differences in age or sex between the two groups.

2.7 | Evaluation method

Testing was conducted at the start of consumption and after 16 weeks. Compliance was confirmed by telephone in the mid-term of the present study. When the subject withdrew from this study or when test-food consumption was discontinued, the study was completed. Furthermore, complications or adverse events were recorded based on reports from subjects. In subjects who had taken drugs for other diseases before the start of the present study, neither the dose nor dosing method was changed during the study period.

A primary evaluation criteria, the Japanese version of the Wechsler Memory Scale-Revised (WMS-R) (Neuner et al., 2007; Wechsler, 1987) consisted of 4 indices: general memory involving verbal and visual memories, and attention/concentration, and 8 subscales (information/orientation, figural memory, logical memory I, visual paired associates I, verbal paired associates I, visual reproduction I, number counting, and visual memory span) comprising the 4 indices. This scale facilitated the global memory assessment. We used 6 subscales in the present study, excluding "visual reproduction I" and "visual memory span." As accessory evaluation criteria (cognitive function tests), we adopted MMSE-J, the Benton Visual Retention Test, Symbol Digit Modalities Test, Cancellation and Detection-Visual Cancellation Task, Trail Making Test (TMT)-Japanese, General Health Questionnaire (GHQ)-12 (Japanese version), and our original questionnaire. Although MMSE-J is used appropriately for the screening of cognitive impairment and dementia in primary care, WMS-R is more suitable for the systematic examination of memory function.

General examination parameters included height, body weight, body mass index (BMI), blood pressure, and pulse rate. Hematological parameters included the leukocyte count, erythrocyte count, hemoglobin (Hb), hematocrit (Ht), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), platelet count, uric acid, urea nitrogen, aspartate aminotransferase (AST)/GOT, alanine aminotransferase (ALT)/GPT, γ-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), lactic acid dehydrogenase (LDH), total bilirubin, total protein, albumin, creatinine (Cre), estimated glomerular filtration rate (GFR), creatine phosphokinase (CPK), serum amylase, total cholesterol, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol, neutral fat, blood glucose, HbA1c, Na, Cl, K, Mg, Ca, Fe, testosterone, and adiponectin (LA). In the urinalysis, qualitative protein/glucose/urobilinogen/bilirubin/occult blood reaction/keratine body tests, as well as specific gravity and pH blood tests were conducted. Blood, urine, and cognitive function tests were generally conducted twice at the start of food consumption and after 16 weeks. Safety assessment items included the number of patients with adverse events, adverse reactions, severe adverse events, or severe adverse reactions/their contents, and the number of patients in whom the oral administration of drugs for dementia was started/their contents. These items were evaluated based on the results of general and blood examinations.
2.8 | Statistical analysis

To compare results between the test-food and placebo groups, differences in scores after the completion of test food consumption from the baseline scores of the respective examination items were investigated using the unpaired t-test. When comparing baseline values between the two groups, sex/age was compared using the chi-squared test and the results of cognitive function tests using the unpaired t-test. We used SPSS Statistics, ver. 25 software. In all tests, two-sided tests were adopted. A p-value of .05 was considered to indicate significant difference.

Since the WMS-R test is recommended for individuals aged ≤75 years, a stratified analysis was performed by dividing subjects into two age groups consisting of those aged 65 to 74 years and those aged ≥75 years, based on the number of subjects. Furthermore, a stratified analysis was conducted by dividing subjects into two groups based on the baseline MMSE-J score (between 24 and 28 and ≥29) for comparisons.

3 | RESULTS

3.1 | Study participants

A flow chart of subjects is shown in Figure 1. The present study was conducted without changing its protocol. Subjects consisted of 38 males and 84 females (total: 122), and they were randomized as described in the Methods. Finally, we analyzed the data from a protocol-matched population (Per Protocol Set: PPS) (n = 108), excluding 4 subjects meeting the exclusion criteria ("exclusion" in Figure 1), 6 subjects who withdrew from the study through discontinuation after the intervention ("withdrew consent" in Figure 1), 2 subjects who were considered to be ineligible by physicians after the intervention ("other" in Figure 1), and 2 subjects with missing data on the main evaluation items ("protocol deviation" in Figure 1). The safety analysis set (SAS) comprised 117 subjects, the full analysis set (FAS) comprised 115 subjects, and the PPS comprised 108 subjects.

The values of the indices are shown in Table 3. In the WMS-R test, 5 indices can be calculated from the results of 8 subtests. The 5 indices consist of "general memory," "visual memory," "verbal memory," "attention/concentration," and "delayed recall." In the present study, 4 index scores, excluding "delayed recall," were obtained (Table 3). Furthermore, 6 subscale scores, excluding "visual reproduction" and "visual memory span," were assessed. In comparisons of the results of the WMS-R test between the test food and placebo groups, the "general memory" index score was significantly higher in the former than in the latter (Table 3), while no significant differences were noted in any subscale score (data not shown). A significant difference was observed in the "visual memory" score comprising "general memory" (Table 3).

The age-stratified analysis of the WMS-R test showed that changes observed in subjects aged ≥74 years were similar to those in the overall subject population. Scores of "general memory" or "visual memory" in the indices of WMS-R were significantly higher in the nobiletin-containing test food group than in the placebo group (Table 4). Furthermore, the "visual paired associates" subscale score in the subscales of WMS-R was significantly higher in the former than in the latter (Table 4). In the stratified analysis involving subjects with an MMSE-J score between 24 and 28, the "figural memory" subscale score in WMS-R was significantly higher in the test food group than in the placebo group (Table 5). On the other hand, no significant differences were observed in any examination item in the subject population with an MMSE-J score of ≥29 (data not shown).

Regarding accessory evaluation items (MMSE-J, Benton Visual Retention Test, Symbol Digit Modalities Test, Cancellation and Detection-Visual Cancellation Task, TMT-Japanese, etc.) in the protocol-matched population (Per Protocol Set: PPS), no significant differences were observed between these groups.
| Variable                  | Active group (n = 54) | Placebo group (n = 54) | p value |
|--------------------------|-----------------------|------------------------|---------|
| Sex (male/female)        | 15/39                 | 18/36                  | .53     |
| Age (years)              | 73.3                  | 72.2                   | .29     |
| Height (cm)              | 155.2                 | 154.7                  | .75     |
| Weight (kg)              | 55.2                  | 56.6                   | .44     |
| BMI (kg/m2)              | 22.9                  | 23.6                   | .25     |
| Blood pressure (mmHg)    |                       |                        |         |
| Systolic                 | 138.1                 | 145.2                  | .08     |
| Diastolic                | 76.3                  | 78.8                   | .30     |
| Pulse                    | 74.6                  | 73.1                   | .53     |
| Cognitive function       |                       |                        |         |
| MMSE-J                   | 28.9                  | 28.6                   | .26     |
| WMS-R (0 min)            | 68.1                  | 66.8                   | .61     |
| BVRT                     | 5.7                   | 5.6                    | .76     |
| SDMT                     | 42.7                  | 41.2                   | .32     |
| CD-VCT time (sec)        | 101.5                 | 108.1                  | .13     |
| CD-VCT response rate (%) | 98.7                  | 98.5                   | .62     |
| TMT                      | 51.2                  | 52.2                   | .77     |
| GHQ−12                   | 37.2                  | 37.3                   | .88     |
| QOL survey               | 18.2                  | 17.6                   | .45     |
| Blood biochemistry       |                       |                        |         |
| Alb (albumin/g/dl)       | 4.3                   | 4.2                    | .24     |
| AST(GOT) (U/L)           | 25.5                  | 23.9                   | .40     |
| ALT(GPT) (U/L)           | 21.6                  | 20.9                   | .82     |
| γ-GTP (IU/L)             | 29.4                  | 33.6                   | .61     |
| Total cholesterol (mg/dl)| 216.4                 | 210.0                  | .40     |
| Triglyceride (mg/dl)     | 145.4                 | 150.0                  | .79     |
| HDL cholesterol (mg/dl)  | 64.0                  | 61.7                   | .49     |
| LDL cholesterol (mg/dl)  | 121.2                 | 119.7                  | .81     |
| Glucose (mg/dl)          | 112.8                 | 115.4                  | .64     |
| HbA1c (NGSP) (%)         | 5.8                   | 5.7                    | .40     |
| eGFR (ml/min/1.73 m²)    | 68.3                  | 69.3                   | .72     |
| Blood urea nitrogen (mg/dl) | 16.5            | 15.7                   | .29     |
| Creatinine (mg/dl)       | 0.7                   | 0.7                    | .82     |
| Adiponectin (μg/ml)      | 13.7                  | 13.1                   | .67     |

Note: Differences between the placebo and active groups were analyzed using the chi-squared test for proportions and the unpaired t-test for means.

Abbreviations: ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; BMI, body mass index; BVRT, Benton Visual Retention Test; CD-VCT, Cancellation and Detection (Visual Cancellation Task); eGFR, estimated glomerular filtration rate; GHQ12, General Health Questionnaire; HbA1c(NGSP), Hemoglobin A1c (National Glycohemoglobin Standardization Program); HDL, High-density lipoprotein; LDL, Low-density lipoprotein; min, minute; MMSE-J, Mini Mental State Examination-Japanese; SDMT, Symbol Digit Modalities Test; sec, second; TMT, Trail Making Test-Japanese; WMS-R, Wechsler Memory Scale-Revised; γ-GTP, Gamma-Glutamyl Transpeptidase.
### TABLE 2  Mean difference from the baseline for cognitive function tests

| Variable        | Active group (n = 54) | Placebo group (n = 54) | p value |
|-----------------|-----------------------|------------------------|---------|
|                 | Mean  | SD   | (95%CI)          | Mean  | SD   | (95%CI)          |
| MMSE-J          | 0.35  | 1.29 | (0.0;0.7)        | 0.46  | 1.45 | (0.86;0.07)      | .68     |
| WMS-R (0 min)   | 9.00  | 7.20 | (7.01;10.92)     | 5.90  | 7.70 | (3.83;8.02)      | .04     |
| BVRT            | 0.57  | 1.75 | (0.11.05)        | 0.57  | 1.37 | (0.20.95)        | 1.00    |
| SDMT            | 1.41  | 4.16 | (0.27;2.54)      | 0.82  | 4.31 | (−0.35;2.0)      | .48     |
| CD-VCT time (sec) | −7.61 | 17.40 | (−12.36;−2.86)  | −4.52 | 16.55 | (−9.04;0.0)     | .35     |
| CD-VCT response rate (%) | 0.06 | 1.53 | (−0.35;0.48) | 0.46 | 1.86 | (−0.05;0.97) | .23 |
| TMT             | −3.39 | 22.91 | (−9.64;2.87)    | −4.78 | 10.95 | (−7.77;−1.79)   | .69     |
| GHQ−12          | 0.94  | 3.67 | (−0.06;1.95)     | 0.39  | 3.45 | (−0.55;1.33)     | .42     |

Note: Differences between the placebo and active groups were analyzed using unpaired t-test for means.

Abbreviations: BVRT, Benton Visual Retention Test; CD-VCT, Cancellation and Detection (Visual Cancellation Task); GHQ12, General Health Questionnaire; Min, minute; MMSE-J, Mini Mental State Examination-Japanese; SDMT, Symbol Digit Modalities Test; Sec, second; TMT, Trail Making Test-Japanese; WMS-R, Wechsler Memory Scale-Revised.

### TABLE 3  Mean difference from the baseline for indices of WMS-R

| Variable       | Active group (n = 54) | Placebo group (n = 54) | p value |
|----------------|-----------------------|------------------------|---------|
|                | Mean  | SD   | (95%CI)          | Mean  | SD   | (95%CI)          |
| General memory | 8.91  | 6.82 | (7.04;10.77)     | 5.87  | 6.99 | (3.96;7.78)      | .02     |
| Visual memory  | 2.52  | 4.64 | (1.25;3.78)      | 0.74  | 3.77 | (−0.29;1.77)     | .03     |
| Verbal memory  | 6.39  | 6.08 | (4.73;8.05)      | 5.13  | 5.94 | (3.51;6.75)      | .28     |
| Attention/ concentration | 0.06 | 2.10 | (−0.52;0.63) | 0.06 | 2.75 | (−0.70.81) | 1.00 |

Note: Differences between the placebo and active groups were analyzed using unpaired t-test for means.

GHQ-12-Japanese, and our original questionnaire), no significant differences were noted between the test food and placebo groups (Tables 2 and 4).

### 3.3 Safety assessment

No significant differences were observed in any parameter in general/blood/urine examinations before and after food consumption between the test food and placebo groups. There were also no adverse events.

### 4 Discussion

Natural medicines have gained popularity in many Western countries in recent years due to their therapeutic effects and affordability for the general public (Rao et al., 2019). With the increasingly extensive application of natural medicines and their bioactive ingredients for disease treatment, clinical studies are imperative to ensure their efficacy and safety.

AD is characterized by impaired cholinergic function. Several anticholinesterase inhibitors, such as donepezil, are clinically used in the treatment of patients with AD. Memory dysfunction generally precedes other cognitive domain dysfunctions in the prodromal phase of AD (Petersen et al., 1999), which is also known as MCI. Memory deficits in neurological and psychiatric patients have been evaluated using neuropsychological tests, such as WMS-R (Neuner et al., 2007; Wechsler, 1987), which is one of the more frequently used measures of memory and attention (Elwood, 1991; Kinno et al., 2017). Niwa et al. (2016) reported that the relationship between WMS-R scores and a decreased regional cerebral blood flow (rCBF) may be important in cognitive assessments of elderly individuals because memory dysfunction precedes other cognitive dysfunctions with prodromal AD (Petersen et al., 1999). The present study assessed the effects of nobiletin-containing test food on the functions of various memory domains in healthy elderly Japanese subjects using the primary outcome, the WMS-R score. The results obtained revealed that in comparison with the placebo treatment, the efficacy of the repeated ingestion of nobiletin-containing test food for improving memory function based on WMS-R scores among healthy elderly subjects, was significantly
### TABLE 4  Mean difference from the baseline for cognitive function tests, indices, and subscales of WMS-R in subjects younger than 74 years old (ages≤74 years)

| Variable                     | Active group (n = 40) | Placebo group (n = 31) | p value |
|------------------------------|-----------------------|------------------------|---------|
|                              | Mean | SD    | (95%CI) | Mean | SD    | (95%CI) |         |
| **Cognitive tests**          |      |       |         |      |       |         |         |
| MMSE-J                       | 0.2  | 1.22  | (−0.19;0.59) | 0.65 | 1.14  | (0.23;1.06) | .12     |
| WMS-R (0 min)                | 9.1  | 7.52  | (6.69;11.51)  | 5.42 | 7.12  | (2.81;8.03)  | .04     |
| BVRT                         | 0.58 | 1.87  | (−0.02;1.17)  | 0.32 | 1.45  | (−0.21;0.85) | .54    |
| SDMT                         | 1.43 | 4.14  | (0.10;2.76)   | 0.65 | 3.38  | (−0.58;1.89) | .4      |
| CD-VCT time (sec)            | −6.43| 12.08 | (−10.29;−2.56) | −3.42| 10.72 | (−7.35;0.51)  | .28     |
| CD-VCT response rate (%)     | 0    | 1.45  | (−0.47;0.46)   | 0.57 | 1.51  | (0.02;1.13)   | .11     |
| TMT                          | −3.6 | 23.16 | (−11.01;3.81)  | −0.81| 8.17  | (−3.80;2.19)  | .52     |
| GHQ−12                       | 1.05 | 3.35  | (−0.02;3.81)   | −0.42| 2.99  | (−1.51;0.68) | .06     |
| **Indices of WMS-R**         |      |       |         |      |       |         |         |
| General memory               | 8.95 | 7.15  | (6.66;11.24)    | 5.39 | 6.81  | (2.89;7.88)   | .04     |
| Visual memory                | 2.6  | 4.49  | (1.16;4.04)    | 0.06 | 3.49  | (−1.22;1.35)  | .01     |
| Verbal memory                | 6.35 | 5.89  | (4.47;8.23)    | 5.32 | 5.92  | (3.15;7.49)   | .47     |
| Attention/Concentration      | 0.15 | 2.18  | (−0.55;0.85)   | 0.03 | 2.95  | (−1.05;1.11)  | .85     |
| **Subscales of WMS-R**       |      |       |         |      |       |         |         |
| Mental control               | 0.05 | 1.04  | (−0.28;0.38)   | −0.1 | 1.35  | (−0.59;0.40) | .61     |
| Figural memory               | 0.55 | 1.65  | (0.02;1.08)    | 0.03 | 1.52  | (−0.52;0.59) | .18     |
| Logical memory               | 5.35 | 4.69  | (3.85;6.85)    | 3.48 | 4.56  | (1.81;5.16)  | .1      |
| Visual paired associates     | 2.05 | 4.28  | (0.68;3.42)    | 0.03 | 3.5   | (−1.25;1.32) | .04     |
| Verbal paired associates     | 1    | 3.2   | (−0.02;2.02)   | 1.84 | 3.08  | (0.71;2.97)  | .27     |
| Digit span                   | 0.1  | 1.89  | (−0.51;0.71)   | 0.13 | 2.33  | (−0.73;0.99) | .95     |

Note: Differences between the placebo and active groups were analyzed using unpaired t-test for means.

General memory: visual memory and verbal memory, visual memory: figural memory and visual paired associates, verbal memory: logical memory and verbal paired associates, attention/concentration: mental control and digit span.

Abbreviations: BVRT, Benton Visual Retention Test; CD-VCT, Cancellation and Detection (Visual Cancellation Task); GHQ12, General Health Questionnaire; Min, minute; MMSE-J, Mini Mental State Examination-Japanese; SDMT, Symbol Digit Modalities Test; Sec, second; TMT, Trail Making Test-Japanese; WMS-R, Wechsler Memory Scale-Revised.

### TABLE 5  Mean difference from the baseline for subscales of WMS-R, in subjects with a MMES-J score of between 24 and 28

| Variable                     | Active group (n = 17) | Placebo group (n = 21) | p value |
|------------------------------|-----------------------|------------------------|---------|
|                              | Mean | SD    | (95%CI) | Mean | SD    | (95%CI) |         |
| Mental control               | 0.29 | 1.31  | (−0.38;0.97)  | −0.19| 1.47  | (−0.86;0.48) | .30     |
| Figural memory               | 0.94 | 1.14  | (0.35;1.53)   | −0.10| 1.64  | (−0.84;0.65) | .03     |
| Logical memory               | 6.24 | 5.17  | (3.58;8.89)   | 4.52 | 3.68  | (2.85;6.2)  | .24     |
| Visual paired Associates     | 1.94 | 4.68  | (−0.47;4.35)  | 0.86 | 4.64  | (−1.25;2.97) | .48     |
| Verbal paired associates     | 1.53 | 3.52  | (−0.28;3.34)  | 1.62 | 3.23  | (0.15;3.09)  | .94     |
| Digit span                   | −0.35| 1.46  | (−0.35;1.11)  | 0.24 | 2.55  | (−0.92;1.4)  | .38     |

Note: Differences between the placebo and active groups were analyzed using unpaired t-test for means.
greater, resulting in significant between-treatment differences (Table 2). The consumption of the test food effectively improved the “visual memory” score (Table 3), suggesting the efficacy of visual care support for improving cognitive function.

In a subgroup analysis of these subjects, improvements in WMS-R were more evident in subjects younger than 75 years than in those older than 75 years (Table 4). In the MMSE-J score-stratified analysis, no significant differences were observed in the population with an MMSE-J score of ≥29, whereas a significant difference was noted in cognitive function in the population with an MMSE-J score of between 24 and 28 (Table 5). Therefore, the nobiletin-containing test food may exert beneficial effects in a group with mild MCI and memory lapses. To the best of our knowledge, the present study is an unprecedented trial that addressed the efficacy of the repeated intake of nobiletin-containing food on cognitive function in healthy elderly subjects assessed by WMS-R. The results obtained appear to be supported by the efficacy of nobiletin against neurodegenerative disorders, such as AD (Braidy et al., 2017; Nakajima & Ohizumi, 2019). Notably, nobiletin exerted memory-improving effects in a number of animal models of AD such as olfactory-bulbectomized mice, Aβ-infused rats, MK-801-treated mice, senescence-accelerated mice, amyloid precursor protein Tg mice, and a rat model of cerebral ischemia Nakajima and Ohizumi (2019). Nobiletin has been shown to exert neuroprotective effects in several in vitro and in vivo studies, by attenuating cholinergic deficits, reducing the abnormal accumulation of neurotoxic amyloid-beta peptides, reversing N-methyl-D-aspartate (NMDA) receptor hypofunction, ameliorating ischemic injury, inhibiting the hyperphosphorylation of tau protein, suppressing β-secretase, increasing neprilysin levels, and modulating several signaling cascades (Braidy et al., 2017; Nakajima & Ohizumi, 2019; Onozuka et al., 2008; Yasuda et al., 2014; Youn et al., 2017). Additionally, the significant distribution of nobiletin in the brain was detected by PET imaging of [11C]-labeled synthetic nobiletin following an intravenous injection in rats (Asakawa et al., 2011) and by the direct measurement of its brain content in nobiletin-administered mice (Saigusa et al., 2011), suggesting the blood-brain permeability of nobiletin. The efficacy and safety of nobiletin-rich C. reticulata peel extract for cognitive function were briefly reported in an intervention study on patients with AD by Seki et al. (2013); cognitive function in six patients with mild-to-moderate AD who were already administered donepezil was assessed with MMSE and the Japanese version of the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-J cog). A one-year intervention with nobiletin-rich C. reticulata peel extract (Chinpi in Kampo medicine) was shown to significantly prevent the progression of cognitive impairments in these patients with no adverse events (Seki et al., 2013). In the present study, the nobiletin-containing test food contains the extracts of K. parviflora and P. japonicum. The K. parviflora extract attenuated cell growth insufficiency at the site of nerve regeneration in the hippocampus (Plaingam et al., 2017). The P. japonicum extract may prolong life by one day due to its anti-obesity (Nugara et al., 2014) and anti-inflammatory activities (Chun et al., 2018). However, the ingredients exhibiting beneficial effect on the memory dysfunction have not been identified in the extracts of K. parviflora and P. japonicum.

5 CONCLUSIONS

In summary, we demonstrated for the first time that nobiletin-containing test food may be beneficial for improving memory dysfunction in healthy elderly subjects.

ACKNOWLEDGEMENTS

The authors thank all participants and caregivers who took part in the study. The following organizations contributed to the implementation of the study as study physicians: Dr. Hideo Hagiwara (Hagiwara Clinic, Shizuoka) and Dr. Naondo Takido (Takido Clinic, Shizuoka). The authors are grateful to Ms. Michiyo Ishida and Ms. Naomi Kajiyama (Center of Michiyo Ishida and Ms. Naomi Kajiyama (Center of Pharma-Food Research, Graduate School of Pharmaceutical Sciences, University of Shizuoka) for their support in conducting this study.

CONFLICT OF INTEREST

All authors declare that they have no conflicts of interest. All authors have approved the final draft of the manuscript.

AUTHOR CONTRIBUTIONS

Shizu Yamada: Conceptualization (equal); Data curation (equal); Funding acquisition (equal); Investigation (equal); Methodology (equal); Project administration (equal); Resources (equal); Supervision (equal); Validation (equal); Visualization (equal); Writing-original draft (equal); Writing-review & editing (equal).

Michiyo Shirai: Data curation (equal); Formal analysis (equal); Methodology (equal); Project administration (equal); Writing-original draft (equal).

Ken Ono: Conceptualization (equal); Data curation (equal); Investigation (equal); Project administration (equal); Supervision (equal); Validation (equal); Visualization (equal).

Toshiaki Teruya: Conceptualization (equal); Project administration (equal); Software (equal); Supervision (equal); Visualization (equal).

Woo Je-Tae: Conceptualization (equal); Funding acquisition (equal); Investigation (equal); Project administration (equal); Resources (equal); Software (equal); Supervision (equal); Validation (equal); Visualization (equal); Writing-original draft (equal); Writing-review & editing (equal).

ETHICAL REVIEW

This study was approved by the Clinical Research Examination Ethical Committee of Hamamatsu Medical University on October 4, 2019. The study conforms to the Declaration of Helsinki, US, and/or European Medicines Agency Guidelines for human subjects.
The potential benefits of nobiletin, a citrus flavonoid, in Alzheimer’s disease have been extensively studied. A recent study by Mulvihill et al. (2019) investigated the effects of nobiletin on oxidative stress and inflammation in Alzheimer’s disease model mice. The findings suggested that nobiletin was able to suppress the expression of pro-inflammatory cytokines and oxidative stress markers, thereby potentially delaying the onset and progression of Alzheimer’s disease.

Choi et al. (2011) demonstrated that nobiletin suppressed adipogenesis by regulating the expression of adipogenic transcription factors and the activation of AMPK. This suppression of adipogenesis could lead to anti-obesity effects, which might also have implications for the treatment of Alzheimer’s disease.

Braidy et al. (2011) explored the suppressive effects of nobiletin on hyperleptinemia and colitis-related colon carcinogenesis in male ICR mice. The study found that nobiletin significantly reduced the levels of leptin and suppressed the growth of colon cancer cells, indicating its potential role in the prevention of colorectal cancer.

Yonezawa et al. (2010) investigated the effects of nobiletin on the expression of pro-inflammatory mediators and suppressed adipogenesis by regulating the expression of adipogenic gene transcription factors and the activation of AMPK. These findings further support the potential anti-inflammatory and anti-obesity effects of nobiletin.

Yamada et al. (2013) tracked pathophysiological processes in Alzheimer’s disease by using the pharmacogenetics of natural products: A pharmacokinetic and pharmacodynamic perspective. They found that nobiletin could suppress amyloid plaques and tau tangles in vivo, which are pathological hallmarks of Alzheimer’s disease.

In conclusion, nobiletin shows promising potential as a therapeutic agent for Alzheimer’s disease, with its ability to regulate inflammation, suppress amyloid plaques and tau tangles, and modulate adipogenesis. Further studies are needed to fully elucidate its mechanisms of action and to develop effective delivery systems for clinical use.

ORCID
Braidy, N., Behzad, S., Habtemariam, S., Ahmed, T., Daglia, M., Nabavi, S. M., Sobarzo-Sanchez, E., & Nabavi, S. F. (2017). Neuroprotective effects of citrus fruit-derived flavonoids, nobiletin and tangeretin in the rat hippocampus: Mechanistic insights into their neuroprotective effects. J Tradit Complement Med, 7, 538–552. https://doi.org/10.1016/j.jtcme.2017.01.002

Prina M (2015) World Alzheimer Report 2015: The global impact of dementia: An analysis of prevalence, incidence, cost and trends. Alzheimer’s Disease International.

Rao, T., Tan, Z., Peng, J., Guo, Y., Chen, Y., Zhou, H., & Ouyang, D. (2019). The pharmacogenetics of natural products: A pharmacokinetic and pharmacodynamic perspective. Pharmacological Research, 146, 104283. https://doi.org/10.1016/j.phrs.2019.104283

Rozkova, J. M., Xiao-Liu, Z., & Guthrie, N. (2007). Effect of citrus flavonoids and tocotrienols on serum cholesterol levels in hypercholesterolemic subjects. Alternative Therapies in Health and Medicine, 13, 44–48.

Saigusa, D., Shibuya, M., Jinno, D., Yamakoshi, H., Iwabuchi, Y., Yokosuka, M., Iimaki, M., Nagamura, A., Ohizumi, Y., Tomioka, Y., & Yamakuni, T. (2011). High-performance liquid chromatography with photodiode array detection for determination of nobiletin content in the brain and serum of mice administrated the natural compound. Analytical and Bioanalytical Chemistry, 400, 3635–3641. https://doi.org/10.1007/s00216-011-5031-2

Seki, T., Kamiya, T., Furukawa, K., Azumi, M., Ishizuka, S. et al (2013). Nobiletin-rich citrus reticulata peels, a Kampo medicine for Alzheimer’s Disease: A case series. Geriatrics & Gerontology International, 13, 236–238.

Tanaka, S., Sato, T., Akimoto, N., Yano, M., & Ito, A. (2004). Prevention of UVB-induced photocarcinogenesis and phototoxiation by a poly-methoxy flavonoid, nobiletin, in human keratinocytes in vivo and in vitro. Biochemical Pharmacology, 68, 433–439. https://doi.org/10.1016/j.bcp.2004.04.006

Wechsler, D. (1987). Manual for the Wechsler memory scale-revised. The Psychological Corporation.

Woo, J. T. (2017). Establishment of high-purity extraction method for nobiletin derived from Citrus depressa and its various physiological activity. Journal of the Taiwan Pharmaceutical Association, 56, 303–308. https://doi.org/10.1016/j.jtpha.2017.09.006
functions. *Japanese Society Medical Use of Funct Foods*, 10, 334–344. (in Japanese).

Yasuda, N., Ishii, T., Oyama, D., Fukuta, T., Agato, Y., Sato, A., Shimizu, K., Asai, T., Asakawa, T., Kan, T., Yamada, S., Ohizumi, Y., & Oku, N. (2014). Neuroprotective effect of nobiletin on cerebral ischemia-reperfusion injury in transient middle cerebral artery-occluded rats. *Brain Research*, 1559, 46–54. https://doi.org/10.1016/j.brainres.2014.02.007

Yasunaga, S., Kadota, A., Kikuchi, T., Kubo, C., Nishi, K., & Sugahara, T. (2016). Effect of concurrent administration of nobiletin and β-lactoglobulin on the symptoms of Japanese cedar pollinosis models in mice. *Journal of Functional Foods*, 22, 389–397. https://doi.org/10.1016/j.jff.2016.01.045

Youn, K., Yu, Y., Lee, J., Jeong, W.-S., Ho, C.-T., & Jun, M. (2017). Polymethoxyflavones: Novel β-secretase (BACE1) inhibitors from citrus peels. *Nutrients*, 9, 973. https://doi.org/10.3390/nu9090973

Zhang, S., Tomata, Y., Sugiyama, K., Sugawara, Y., & Tsuji, I. (2017). Citrus consumption and incident dementia in elderly Japanese: The Ohsaki Cohort 2006 Study. *British Journal of Nutrition*, 117, 1174–1180. https://doi.org/10.1017/S000711451700109X

**How to cite this article:** Yamada, S., Shirai, M., Ono, K., Teruya, T., Yamano, A., & Tae Woo, J. (2021). Beneficial effects of a nobiletin-rich formulated supplement of Sikwasa (C. depressa) peel on cognitive function in elderly Japanese subjects: A multicenter, randomized, double-blind, placebo-controlled study. *Food Science & Nutrition*, 9, 6844–6853. https://doi.org/10.1002/fsn3.2640